Anti-human CD10 MME Monoclonal Antibody APC Conjugated, Flow Validated

CD10, also known as membrane metallo-endopeptidase, neutral endopeptidase (NEP), Neprilysin, or common acute lymphoblastic leukemia antigen (CALLA), is a zinc-dependent metalloprotease enzyme that degrades a number of small secreted peptides, most notably theamyloid beta peptide whose abnormal misfolding and aggregation in neural tissue has been implicated as a cause of Alzheimer's disease. This gene is localized to human chromosome 3 by study of somatic cell hybrids and regionalized the location to 3q21-q27 by in situ hybridization. By cDNA transfection analysis, CD10 is confirmed as a functional neutral endopeptidase of the type that has previously been called enkephalinase. CD10 has also been called atriopeptidase. Atriopeptidase specifically degrades atrial natriuretic factor. A specific enzyme inhibitor was developed and reported that it had effects similar to those of low-dose ANF infusion. These effects include diuresis, natriuresis, vasodilatation, and suppression of the renin-angiotensin-aldosterone system.

Neprilysin;3.4.24.11 ; Atriopeptidase; Common acute lymphocytic leukemia antigen; CALLA; Enkephalinase; Neutral endopeptidase 24.11; NEP; Neutral endopeptidase; Skin fibroblast elastase; SFE; CD10; MME; EPN

Angiogenesis, Atherosclerosis, Cancer, Cardiovascular, Cytoskeleton/ECM, ECM Enzymes, Extracellular Matrix, Invasion/Microenvironment, Signal Transduction, Tumor Biomarkers

Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:8168535) . Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:17101991) . Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:15283675) . Involved in the degradation of atrial natriuretic factor (ANF) (PubMed:2531377, PubMed:2972276) . Displays UV-inducible elastase activity toward skin preelastic and elastic fibers (PubMed:20876573) . .